All Pre-Conference Workshops will be held on Monday, July 10, 2022
1:00 p.m. – 4:00 p.m.
Lunch is not included but we will have a refreshment break mid-workshop.
Fee: $65.00 USD
Stem Cell Network is pleased to host the “3D Bioprinting: Principles and Strategies for Tissue Engineering and Regenerative Medicine” as part of the TERMIS-AM meeting in partnership with Aspect Biosystems and Fluidform Inc. Tissue engineering holds the potential to transform drug discovery and clinical practice for regenerative medicine. While the creation of whole organs is a long-term goal, 3D bioprinted tissues already show promise in improving patient care as implantable therapeutic tissues and as more predictive models in drug development.
A multitude of strategies have arisen to recapitulate the structural and functional complexity of human tissue using additive manufacturing methods. A common challenge in the field is that biomaterials that preserve cell viability and promote function may not meet the structural and mechanical requirements of the application. This workshop focuses on strategies to overcome this and other challenges in tissue engineering using extrusion-based bioprinting methods.
The workshop will feature expert speakers working in the field and a panel discussion with industry leaders on the commercialization and translation of 3D bioprinting. The talks will be followed by technology demonstrations of Aspect Biosystems’ microfluidic 3D bioprinting technology and FluidForm’s FRESH printing platform. Both technologies offer strategies for creating complex tissue structures while promoting tissue function.
About Aspect Biosystems:
Aspect Biosystems is a biotechnology company creating bioprinted tissue therapeutics to transform how we treat disease. Aspect’s microfluidic 3D bioprinting technology uses microfluidic printheads to create hydrogel fibres with complex microarchitectures that can be patterned and matured into 3D tissue constructs. Through our internal programs and collaborations, we are working towards using these tissue constructs as implantable therapeutics for conditions such as type 1 diabetes and liver failure.
FluidForm’s FRESH technology works by extruding bioinks and other materials within LifeSupport – a specially formulated support bath that maintains the shape of soft materials during printing and is then gently melted away at physiologic temperatures. The technology is being used to precisely replicate the structure and function of human tissue to develop better disease models for drug discovery, create bioprosthetic and regenerative medical devices to restore function and engineer tissue and organs that will replace transplants.
- Introduce attendees to basic concepts of 3D bioprinting, including an overview of the technology and an understanding of the advantages and capabilities
- Have an understanding of current and future applications for 3D bioprinting, including the benefits and challenges associated with different use scenarios
- Expose attendees to demonstrations of the 3D bioprinting hardware, software and platform technologies used to design and produce 3D bioprinted tissues
From bench to boardroom: Commercializing your RM product or therapy
The global regenerative medicine market was valued at US$23.8 billion (2018), and it is anticipated to grow to US$151 billion by 2026 with an annual growth rate of 26.1 per cent. Cell and gene therapies are being approved and reimbursed. It’s an exciting time to be an entrepreneur in this field. Join CCRM experts and special guests for a brief but helpful overview of the main issues to consider in your entrepreneurial journey from innovator to business leader. A taught case study will cover some of the main points to consider when taking your product or therapy to the marketplace. The afternoon will culminate with a thought-provoking and insightful keynote address from a well-respected leader in the field. You will walk away from this workshop feeling more knowledgeable, confident and inspired.
1:00 – 1:15 p.m. Welcome and introduction by Michael May
1:15 – 2:45 p.m. Six teaching talks*, 15 minutes. CCRM experts to lead
2:45 – 3:15 p.m. Participants, paired with invited guests from academia and industry (minimum one per table), to briefly discuss the case study now that they have heard from the experts; group wrap up with all participants
3:15 – 4 p.m. Keynote
*Talks will cover:
- How Tech Transfer Offices work
- Manufacturing and process development
- Financing for early start-ups
- Financial planning
This workshop, being organized by Dr. Emilio I. Alarcón at the University of Ottawa Heart Institute & Faculty of Medicine, University of Ottawa, aims to review the current state of the art of biomaterials for cardiac research. We will cover aspects from the material design, fabrication, in vitro & in vivo testing to the preclinical testing & regulatory considerations for use in humans. Participants in the workshop will be part of a dynamic afternoon with speakers from different backgrounds working in the field spanning from chemistry, physics, cell biology, and clinical research in cardiac health.
|1:00 – 1:05||Opening remarks|
|1:05 – 1:25||Chemical considerations in the design of biomaterials for cardiac tissue repair|
|1:25 – 1:45||How to best evaluate the physical properties of a given biomaterial for cardiac applications?|
|1:45 – 2:05||How can we evaluate cell biomaterial interactions?|
|2:05 – 2:30||Round Table: Q&A for Part I|
|2:55 – 3:15||Coffee Break & Networking|
|2:55 – 3:15||In vivo assessment of performance of biomaterials in cardiac therapies|
|3:15 – 3:35||Pre-clinical testing and regulatory considerations for biomaterials in the cardiac field|
|3:35 – 3:55||Round Table: Q&A for Part II|
|3:55 – 4:00||Closing remarks|
There is no content